Pictet Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Pictet Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.57M	Buy	38,198 +620	+2%	+$43.3K	﹤0.01%	865
2025 Q4	$3.08M	Sell	37,578 -36,069	-49%	-$2.69M	﹤0.01%	849
2025 Q3	$4.28M	Sell	73,647 -6,573	-8%	-$324K	﹤0.01%	808
2025 Q2	$3.24M	Sell	80,220 -4,477	-5%	-$201K	﹤0.01%	827
2025 Q1	$4.38M	Buy	84,697 +79,567	+1,551%	+$3.93M	﹤0.01%	818
2024 Q4	$284K	Buy	+5,130	New	+$233K	﹤0.01%	1670

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pictet Asset Management's TARS Position: Q1 2026 in Review

Pictet Asset Management increased its Tarsus Pharmaceuticals (TARS) stake by 1.6% in Q1 2026, buying an estimated $43.3K and bringing the position to 38,198 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Pictet Asset Management first reported a position in TARS in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.38M in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Pictet Asset Management held 38,198 shares of Tarsus Pharmaceuticals worth $2.57M as of Q1 2026.
Pictet Asset Management bought 620 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $43.3K.
Tarsus Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #865 holding.
Pictet Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Pictet Asset Management's Tarsus Pharmaceuticals position peaked at $4.38M in Q1 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.